Kangmei Pharmaceutical Co., Ltd.

Money comes from selling finished medicine, decoction pieces, devices and food to the parties that take control of them, mainly hospitals and medical institutions, distributors, chain pharmacies, and retail or e-commerce buyers, plus a smaller stream from property sales and leasing. Income is booked when goods change hands rather than through subscriptions, licensing or recurring service fees.

CompanyGraph reads its recent financing pattern as scaling through issuing more shares while long-term debt has been falling, with total financing activity large relative to cash generated by operations, rather than growth funded mainly from retained profit. Earnings on the operating side have been uneven, including a period of significant loss followed by several years of modest positive income, even as the company continues to fund named capacity projects at its production sites.

The company depends on the supply of traditional Chinese medicinal materials, which it buys from producing-region suppliers, farmers and professional medicinal-material markets, supplemented by its own and jointly built cultivation bases. It names this material supply, exposed to weather, natural disaster, scarcity and policy, and its purchasing costs as risks outside its control, and a meaningful share of its buying is concentrated among a small number of suppliers, including related parties.

Its declared customers span hospitals and other medical institutions, pharmaceutical wholesalers and distributors, chain pharmacies, retail and e-commerce buyers, and enterprise group-buying customers, and it counts a broad network of medical institutions and pharmacies as business relationships. Even so, a small group of its largest customers accounts for a substantial share of its yearly sales.

CompanyGraph places this company alongside a large number of other companies that operate under the same regulatory-approval-driven production model common to its industry, so the basic shape of its operations is common rather than rare within its category. The company itself claims an advantage in running the full chain, from raw-material cultivation and market operation through manufacturing to hospital, pharmacy and retail distribution, under one roof, but CompanyGraph has no evidence on file showing whether other companies can or cannot copy that same span.

In its own account, the company points to the supply and price of raw traditional Chinese medicinal material as a direct constraint on cost control and production planning, alongside the rising cost of meeting stricter quality, traceability, environmental and safety standards. This differs from the approval-driven bottleneck that typically defines companies in its broader regulatory category, where the limit is usually clearing a regulatory gate rather than securing and pricing a raw material.

The company discloses concentration on both sides of its business: a small number of customers account for a large share of its sales, and a small number of suppliers, including related parties, account for a substantial share of its purchases. It also discloses ongoing litigation and enforcement matters, including a creditor's enforcement action and a rejected bankruptcy-liquidation appeal against one of its market subsidiaries, disclosures that sit alongside its own account of an earlier court-confirmed restructuring.

The company names regulatory bodies covering health, traditional medicine and drug administration at national and provincial level, along with securities regulators and its stock exchange, as authorities it operates under. In its own risk disclosures it ranks tightening industry regulation and policy change first, ahead of competitive pressure and the pricing and supply effects of centralized bulk procurement of decoction pieces, with raw-material availability and cost named as a further pressure.